Don't forget traditional DMARDs

Rheumatology

Volumn 50, Issue 3, 2011, Pages 429-430

  Fleischmann, Roy ^a  

^a UNIVERSITY OF TEXAS SOUTHWESTERN MEDICAL CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ADALIMUMAB; DISEASE MODIFYING ANTIRHEUMATIC DRUG; GOLIMUMAB; INFLIXIMAB; LEFLUNOMIDE; METHOTREXATE; SALAZOSULFAPYRIDINE;

DISEASE COURSE; DRUG TOLERABILITY; EDITORIAL; GOLD STANDARD; HUMAN; OUTCOME ASSESSMENT; PRIORITY JOURNAL; REMISSION; RHEUMATOID ARTHRITIS; TREATMENT RESPONSE;

ANTIRHEUMATIC AGENTS; ARTHRITIS, RHEUMATOID; HISTORY, 19TH CENTURY; HISTORY, 20TH CENTURY; HISTORY, 21ST CENTURY; HUMANS; TREATMENT OUTCOME;

EID: 79952020414     PISSN: 14620324     EISSN: 14620332     Source Type: Journal    
DOI: 10.1093/rheumatology/keq382     Document Type: Editorial

References (17)

1. Davies HR, Barter RW, Gee A, Hirson C. Observations on the use of butazolidin in arthritis. Br Med J 1952;2:1392-4.
2. Freedman A, Steinberg VL. Chloroquine in rheumatoid arthritis; a double blindfold trial of treatment for one year. Ann Rheum Dis 1960;19:243-50.
3. Williams JH. Rheumatoid arthritis: treatment. In: Schumacher HR Jr, ed. Primer of the Rheumatic Disease. Atlanta: The Arthritis Foundation, 1993:96-9.
4. Smolen JS, Aletaha D, Bijlsma JW et al. Treating rheumatoid arthritis to target: recommendations of an international task force. Ann Rheum Dis 2010;69:631-7.
5. Weinblatt ME, Coblyn JS, Fox DA et al. Efficacy of low-dose methotrexate in rheumatoid arthritis. N Engl J Med 1985;312:818-22.
6. Weinblatt ME, Kaplan H, Germain BF et al. Low-dose methotrexate compared with auranofin in adult rheumatoid arthritis. A thirty-six-week, double-blind trial. Arthritis Rheum 1990;33:330-8.
7. Weinblatt ME, Polisson R, Blotner SD et al. The effects of drug therapy on radiographic progression of rheumatoid arthritis. Results of a 36-week randomized trial comparing methotrexate and auranofin. Arthritis Rheum 1993;36:613-9.
8. Pincus T, Ferraccioli G, Sokka T et al. Evidence from clinical trials and long-term observational studies that disease-modifying anti-rheumatic drugs slow radiographic progression in rheumatoid arthritis: updating a 1983 review. Rheumatology 2002;41:1346-56.
9. Strand V, Cohen S, Schiff M et al. Treatment of active rheumatoid arthritis with leflunomide compared with placebo and methotrexate. Leflunomide Rheumatoid Arthritis Investigators Group. Arch Intern Med 1999;159: 2542-50.
10. Smolen JS, Kalden JR, Scott DL et al. Efficacy and safety of leflunomide compared with placebo and sulphasalazine in active rheumatoid arthritis: a double-blind, randomised, multicentre trial. European Leflunomide Study Group. Lancet 1999;353:259-66.
11. Pincus T, Marcum SB, Callahan LF. Longterm drug therapy for rheumatoid arthritis in seven rheumatology private practices: II. Second line drugs and prednisone. J Rheumatol 1992;19:1885-94.
12. Bathon JM, Martin RW, Fleischmann RM et al. A comparison of etanercept and methotrexate in patients with early rheumatoid arthritis. N Engl J Med 2000;343: 1586-93.
13. Fleischmann RM. Comparison of the efficacy of biologic therapy for rheumatoid arthritis: can the clinical trials be accurately compared? Rheum Dis Clin North Am 2006; 32(Suppl. 1):21-8.
14. Fleischmann R. The clinical efficacy and safety of certolizumab pegol in rheumatoid arthritis. Expert Opin Biol Ther 2010;10:773-86.
15. Fleischmann R. The efficacy and safety of golimumab in the treatment of arthritis. Expert Opin Biol Ther 2010;10: 1131-43.
16. Cohen S, Fleischmann R. Kinase inhibitors: a new approach to rheumatoid arthritis treatment. Curr Opin Rheumatol 2010;22:330-5.
17. Kremer JM, Bloom BJ, Breedveld FC et al. The safety and efficacy of a JAK inhibitor in patients with active rheumatoid arthritis: results of a double-blind, placebo-controlled phase IIa trial of three dosage levels of CP-690,550 versus placebo. Arthritis Rheum 2009;60: 1895-905.